APPART study
Completed
- Conditions
- Pancreatic ductal adenocarcinoma (PDAC)
- Registration Number
- NL-OMON20200
- Lead Sponsor
- Department of Surgery, Erasmus Medical Center Rotterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Patients aged 18 years or older with treatment naïve pancreatic ductal adenocarcinoma who will either undergo staging laparoscopy for locally advanced disease, or tumor resection for (borderline) resectable disease.
Exclusion Criteria
prior appendectomy, prior malignancy within the past 5 years, prior chemotherapy or radiotherapy within the past 5 years, pregnancy, participation in the PREOPANC-2 trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The level of PDAC-specific oncolytic activity of vermiform appendix derived T lymphocytes
- Secondary Outcome Measures
Name Time Method Identification of<br>- PDAC specific antigens<br>- appendix fecal microbiome diversity<br>- molecular immune landscapes in the vermiform appendix sana from patients with PDAC compared to controls<br>- differential T-cell and B-cell receptor repertoires in peripheral blood lymphocytes vs lymphocytes from the vermiform appendix, in patients with PDAC.